Peptides DB
Research-centric peptide and protocol reference hub
Study 8 of 9Lixisenatide literatureNatureTop journal2025

Lymphoid gene expression supports neuroprotective microglia function.

Not reported in abstract.

Read at NatureAdd to compare

Where it sits

this study against the rest of the lixisenatide corpus
2
Preclinical · this one
3
Observational
0
Open-label
2
Randomised
2
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2025

Abstract

The authors’ words, as Nature supplied them

Microglia, the innate immune cells of the brain, play a defining role in the progression of Alzheimer's disease (AD)<sup>1</sup>. The microglial response to amyloid plaques in AD can range from neuroprotective to neurotoxic<sup>2</sup>. Here we show that the protective function of microglia is governed by the transcription factor PU.1, which becomes downregulated following microglial contact with plaques. Lowering PU.1 expression in microglia reduces the severity of amyloid disease pathology in mice and is linked to the expression of immunoregulatory lymphoid receptor proteins, particularly CD28, a surface receptor that is critical for T cell activation<sup>3,4</sup>. Microglia-specific deficiency in CD28, which is expressed by a small subset of plaque-associated PU.1<sup>low</sup> microglia, promotes a broad inflammatory microglial state that is associated with increased amyloid plaque load. Our findings indicate that PU.1<sup>low</sup> CD28-expressing microglia may operate as suppressive microglia that mitigate the progression of AD by reducing the severity of neuroinflammation. This role of CD28 and potentially other lymphoid co-stimulatory and co-inhibitory receptor proteins in governing microglial responses in AD points to possible immunotherapy approaches for treating the disease by promoting protective microglial functions.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Lixisenatide corpus

DHow short peptides disassemble tau fibrils in Alzheimer's disease.Nature · 2025BReal-World Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Weight Recurrence After Bariatric Surgerybiorxiv-preprint · 2025 · 9.6% weight loss vs 4.3% in non-users at 6 months, p = 0.005.HumanAEfficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.Diabetes, obesity & metabolism · 2026 · n=582 · HbA1c reductions were greater with iGlarLixi versus IDegAsp at Week 24.HumanAHypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.Endocrine · 2025 · n=10880 · OR 0.91, CI 0.57-1.47 for HDP risk with GLP-1 RA exposure.reviewBComparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk.Journal of the American Society of Nephrology : JASN · 2026 · n=160428 · SGLT2i users had a hazard ratio of 0.89 for kidney failure risk compared to GLP-1 RA users.HumanDAssociation of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2024 · Liraglutide ROR = 3.26, 95% CI = 2.53, 4.22 for suicidal ideation.review